Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

Patients using GLP-1 drugs had no difference in the odds of postoperative aspiration pneumonia versus non-users. Preoperative ...

How should you guide patients on GLP-1 therapy who are planning pregnancy? Dr Almandoz breaks down when to stop treatment, ...

In recent years, the growing list of medical benefits for GIP and GLP-1 agonists (think Ozempic for diabetes or Zepbound for ...

South Africa's Aspen Pharmacare has started registering GLP-1 drugs used to treat diabetes and obesity in markets where ...

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...

The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older adults with type 2 diabetes ...

A boost for the category, and perhaps even a change in the way products are marketed, is anticipated based on research ...

Weight-loss drugs are changing the way people grocery shop and eat. But those spending habits don't necessarily last.

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

GLP-1 receptor agonists were initially approved for glycaemic control in type 2 diabetes and, subsequently, for bodyweight loss in obesity. Following large-scale trials demonstrating that some GLP-1 ...